Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/23/2019 |
| Start Date: | September 1, 2018 |
| End Date: | September 30, 2022 |
| Contact: | Jason R Tregellas, PhD |
| Email: | Jason.Tregellas@va.gov |
| Phone: | (303) 315-1086 |
This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and
cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure
drug, also called an anticonvulsant.
cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure
drug, also called an anticonvulsant.
Cognitive symptoms are not currently well-managed in Veterans with schizophrenia, leading to
substantially diminished quality of life. Improved treatment strategies clearly are needed.
Recent studies suggest taht an overactive hippocampus is associated with cognitive deficits
in the illness. Based on findings that the anti-epileptic drug levetiracetam (LEV) reduces
hippocampal activity and improves cognition in other clinical populations while being safe
and well-tolerated, this study will examine the effects of the drug on hippocampal activity
and cognition in Veterans with schizophrenia. In this crossover design, participants will
take LEV for 4 weeks and placebo pills for 4 weeks, but will not know the order in which they
are taking them.
substantially diminished quality of life. Improved treatment strategies clearly are needed.
Recent studies suggest taht an overactive hippocampus is associated with cognitive deficits
in the illness. Based on findings that the anti-epileptic drug levetiracetam (LEV) reduces
hippocampal activity and improves cognition in other clinical populations while being safe
and well-tolerated, this study will examine the effects of the drug on hippocampal activity
and cognition in Veterans with schizophrenia. In this crossover design, participants will
take LEV for 4 weeks and placebo pills for 4 weeks, but will not know the order in which they
are taking them.
Inclusion Criteria:
- Diagnosis of schizophrenia or schizoaffective disorder
- Good general health
- Normal vital signs (blood pressure, pulse, respiration)
Exclusion Criteria:
- Substance abuse
- Significant neurological disorders
- Significant head trauma/injury
- Pregnancy
- MRI-specific exclusion criteria, e.g.,:
- claustrophobia
- weight>400 lbs
- metal in the body
We found this trial at
1
site
Aurora, Colorado 80045
Principal Investigator: Jason R. Tregellas, PhD
Phone: 303-315-1086
Click here to add this to my saved trials
